Suchergebnisse - "Rahman, Omar"

PubPharm (20)

1

Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid : a secondary analysis of a randomized study

enthalten in: Expert opinion on drug safety | 2018

von Abdel-Rahman, O.

2

Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments

enthalten in: Expert opinion on drug safety | 2016

von Ahmed, S. | Moussa Sherif, D. | Fouad, Y. | +2

3

S-1-based regimens and the risk of oral and gastrointestinal mucosal injury : a meta-analysis with comparison to other fluoropyrimidines

enthalten in: Expert opinion on drug safety | 2016

von Abdel-Rahman, O. | ElHalawani, H. | Essam-Eldin, S.

4

S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines

enthalten in: Expert opinion on drug safety | 2016

von Abdel-Rahman, O. | ElHalawani, H. | Essam-Eldin, S.

5

S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines

enthalten in: Expert opinion on drug safety | 2016

von Abdel-Rahman, O. | ElHalawani, H. | Essam-Eldin, S.

6

Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments

enthalten in: Expert opinion on drug safety | 2016

von Ahmed, S. | Moussa Sherif, D. | Fouad, Y. | +2

7

S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines

enthalten in: Expert opinion on drug safety | 2016

von Abdel-Rahman, O. | ElHalawani, H. | Essam-Eldin, S.

8

S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines

enthalten in: Expert opinion on drug safety | 2016

von Abdel-Rahman, O. | ElHalawani, H. | Essam-Eldin, S.

9

S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines

enthalten in: Expert opinion on drug safety | 2016

von Abdel-Rahman, O. | ElHalawani, H. | Essam-Eldin, S.

10

Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments

enthalten in: Expert opinion on drug safety | 2016

von Ahmed, S. | Moussa Sherif, D. | Fouad, Y. | +2